Skip to content

Author

Fu-Jun Wang

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

FerrGAT: Multi-Task Pre-Training of Graph Attention Networks for Low-Data Molecular Activity Prediction

Predicting molecular bioactivity in low-data regimes remains a central challenge in computational drug discovery, where labeled compounds for specialized tasks are scarce while related datasets are abundant. Here, we propose FerrGAT, a graph attention network framework that addresses this challenge through domain-relevant multi-task pre-training and dual-channel molecular representation learning. FerrGAT first pre-trains a shared GAT encoder on three mechanistically related tasks—antioxidant activity (GST inhibition, 245 compounds from ChEMBL target CHEMBL2095173; 83 active/162 inactive), kinase inhibition (3000 compounds spanning AXL, EGFR and VEGFR2 from ChEMBL; 2240 active/760 inactive), and cellular toxicity (7265 compounds from the Tox21 NR-AhR endpoint; 309 active/6956 inactive)—then transfers the learned representations to a target task via differential learning rate fine-tuning. The architecture fuses atom-level graph features from multi-head attention message passing with global physicochemical descriptors through a learned projection and provides built-in interpretability via attention weight visualization at the atomic level. We evaluated FerrGAT on ferroptosis inhibitor prediction as a representative low-data molecular classification task (1052 compounds from ChEMBL targets GPX4 and HMOX1 combined with 63 literature- and FerrDb-curated ferroptosis modulators; 409 active/643 inactive). In 5-fold cross-validation, FerrGAT achieved an AUC of 0.906, outperforming Morgan fingerprint baselines, including Random Forest (0.877), XGBoost (0.871), and an SVM (0.873). Ablation studies confirmed that domain-relevant pre-training improved AUC by 2.5% over training from scratch, while pre-training on unrelated tasks degraded performance, highlighting the importance of task-domain alignment. Applied to virtual screening of 30 FDA-approved tyrosine kinase inhibitors, the model identified Bemcentinib (AXL inhibitor, score = 0.918) as a top candidate, validated by AutoDock Vina molecular docking (−8.51 kcal/mol) and independent experimental evidence, including lipid peroxidation assays, Western blot, and cellular thermal shift analysis. These results demonstrate that domain-aware transfer learning with graph attention networks provides an effective and interpretable framework for molecular property prediction in data-limited scenarios.

Shichong Liu, Siqi Wei, Jian Zhao et al. · 0 citations
Open access Aug 2026

TROP2-targeting chimeras (TRTACs) for tumor-selective membrane protein degradation and enhanced drug delivery

Extracellular targeted protein degradation (eTPD) systems typically utilize lysosome-targeting receptors (LTRs) to mediate internalization and lysosomal degradation of extracellular and membrane proteins. While multiple LTRs have been discovered, there remains a compelling need to seek for new LTRs, particularly those with clear clinical relevance, to expand the therapeutic potential of eTPD. Here we report trophoblast cell surface antigen-2 (TROP2), a clinically validated tumor-associated antigen, as a promising tumor-selective LTR. We engineer TROP2-targeting chimeras (TRTACs) by genetically fusing a TROP2-binding nanobody to nanobodies against specific target proteins. We show that TRTACs can induce tumor cell-selective degradation of diverse membrane proteins, including epithelial growth factor receptor (EGFR), human epithelial growth factor receptor 2 (HER2), and programmed death-ligand 1 (PD-L1). The EGFR-targeted TRTAC significantly inhibits tumor cell proliferation and shows potent antitumor activity in vivo. We further design TRTAC-drug conjugates (TRTAC-DCs) by attaching cytotoxic payloads to TRTACs, enabling targeted protein degradation together with enhanced drug delivery. TRTAC-DCs show significantly enhanced activity against HER2- and EGFR-positive tumors both in vitro and in vivo, with minimal toxicity observed in normal tissues. These findings establish TROP2 as a robust LTR and provide a versatile eTPD platform with profound translational potential for tumor treatment.

Luping Chen, Xinying Fu, Wenqian Dong et al. · 0 citations